Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
The primary objective of this study is to evaluate the efficacy, safety and tolerability of
 treatment with sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) with ribavirin (RBV) for 24 weeks
 in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead
 sponsored study and did not achieve sustained virologic response (SVR).
Key Inclusion Criteria:

 -  Willing and able to provide written informed consent

 -  HCV genotype determined by the Central Laboratory

 -  HCV RNA > LLOQ at screening

 -  Participated and completed a Gilead sponsored HCV treatment study of direct acting
 antiviral (DAA) containing regimens.

 -  Male and female of childbearing potential must agree to use protocol specified
 method(s) of contraception

 Key Exclusion Criteria:

 -  Current or prior history: Clinically-significant illness (other than HCV) or any other
 major medical disorder that may interfere with treatment, assessment or compliance
 with the protocol; individuals currently under evaluation for a potentially
 clinically-significant illness (other than HCV) are also excluded.

 -  Screening ECG with clinically significant abnormalities

 -  Laboratory results outside of acceptable ranges at screening

 -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

 NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.